Lyra Therapeutics, Inc. Q2 FY2020 earnings call

• Successful initial public offering on NASDAQ in May 2020, raising $64 million in gross proceeds.
• Appointed Dr. Robert Richards as Senior Vice President of Research and Development and Pamela Nelson as Senior Vice President of Regulatory Affairs.
• LANTERN Phase 2 trial for LYR-210 completed enrollment of 67 patients (impacted by COVID-19), with over 60 patients having completed 24 weeks of treatment, expecting top-line data by year-end.
• LYR-220 in early planning for proof of concept clinical trial.
• Introduction of Lyra's XTreo platform for drug delivery, with potential applications in additional ENT indications.

No detailed product segment financials with absolute terms and revenue contribution % were provided in the transcript.

• Current cash balance of $86.6 million (including IPO proceeds) is sufficient to fund Phase 3 study of LYR-210.
• Projected year-end 2020 cash balance in the range of $67 million to $70 million.

• COVID-19 impact on clinical trial site operations, though LANTERN trial data collection via electronic diaries less affected.
• Data monitoring committee assesses safety based on expert judgment, with no pre-established threshold for requiring modifications.

Q: About the data monitoring committee and what constitutes an adverse event profile requiring modification; A: The monitoring committee, composed of experienced ENTs, assesses safety based on their expertise; no pre-established threshold, they propose changes as they see fit.

Q: Split of polyp vs non-polyp patients in the trial; A: Approximately 50-50 split in the trial, and compares efficacy but trials differ in endpoints.

Q: Impact of COVID-19 on end of study removal procedure; A: Minimal impact so far, sites operational, remaining patients' visits scheduled in August to complete.

Q: CRS patient visits affected by COVID-19; A: Office visits mostly recovered, but surgeries still lagging